NewAmsterdam Pharma (NAMS) Total Liabilities (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Total Liabilities data on file, last reported at $67.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 64.24% year-over-year to $67.4 million; the trailing twelve-month figure through Mar 2026 stood at $67.4 million (up 64.24% YoY), and the FY2025 full-year result was $85.9 million, down 19.85% from the prior year.
• Total Liabilities declined to $67.4 million in Q1 2026, from $85.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $542.3 million in Q4 2022 to a low of $512990.1 in Q2 2023.
• A 5-year average of $99.5 million and a median of $59.8 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities tumbled 89.18% in 2023 and jumped 11450.13% in 2024, its largest moves.
• Tracing NAMS's Total Liabilities over 5 years: stood at $542.3 million in 2022, then plunged by 89.18% to $58.7 million in 2023, then surged by 82.47% to $107.1 million in 2024, then dropped by 19.85% to $85.9 million in 2025, then fell by 21.47% to $67.4 million in 2026.
• Business Quant data shows NAMS's Total Liabilities at $67.4 million in Q1 2026, $85.9 million in Q4 2025, and $58.4 million in Q3 2025.